Pascal Soriot | Chief Executive Officer |
Dave Fredrickson | Executive Vice President of the Oncology Business Unit |
Ruud Dobber | Executive Vice President of the Biopharmaceuticals Business Unit |
Marc Dunoyer | Executive Director and Chief Financial Officer |
Mene Pangalos | Executive Vice President of the Biopharmaceuticals R&D Group |
Jose Baselga | Executive Vice President of Oncology R&D |
Pam Cheng | Executive Vice President of Operations and IT |
Leon Wang | Executive Vice President for the China and Emerging Markets |
Andrew Baum | Citi |
Luisa Hector | Berenberg |
Richard Parkes | Exane |
Steve Scala | Cowen |
Sachin Jain | Bank of America |
Keyur Parekh | Goldman |
Mark Purcell | Morgan Stanley |
Tim Anderson | Wolfe Research |
Seamus Fernandez | Guggenheim |
Matt Weston | Credit Suisse |
James Gordon | JP Morgan |
Peter Welford | Jefferies |
Simon Baker | Redburn |
Good morning to those joining from the U.K. and the U.S. Good afternoon to those in Central Europe. Welcome, ladies and gentlemen, to AstraZeneca’s year-to-date presentation conference call and webcast for investors and analysts.
Before I hand over to AstraZeneca, I would like to read the safe harbor statement.